Vita Therapeutics specializes in cell engineering techniques to regenerate damaged tissues and organs, utilizing precise cell manipulation to enhance recovery outcomes for patients with degenerative diseases. The company addresses the limitations of existing therapies by providing targeted cellular interventions that improve tissue repair and functionality.
Funding
$65.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CBSFFounders
Product
Problem
Current treatments for degenerative diseases often fail to fully restore tissue and organ function due to the limitations of traditional regenerative medicine approaches. These methods may lack the precision needed to replace defective cells with healthy, functional ones, hindering effective tissue repair and long-term recovery.
Solution
Vita Therapeutics is a cell engineering company focused on developing cell therapies to regenerate damaged tissues and organs. The company leverages induced pluripotent stem cells (iPSCs) and genetic engineering to create specific cell types designed to replace defective cells in patients. Vita Therapeutics employs both autologous and allogeneic approaches to deliver these engineered cells, offering patient-specific and universal therapy options. By harnessing the power of genetics and precise cell manipulation, Vita Therapeutics aims to unlock the potential of engineered cellular medicine and provide life-transformative treatments for degenerative diseases.
Target Audience
The primary target audience includes patients suffering from degenerative diseases, particularly those with muscular dystrophies like LGMD2A and FSHD, as well as clinicians and researchers in the field of regenerative medicine.
Features
- Utilizes induced pluripotent stem cells (iPSCs) derived from somatic cells through temporary expression of Yamanaka Factors.
- Employs cell engineering techniques to create specific cell types for targeted tissue regeneration.
- Offers both autologous (patient-specific) and allogeneic (universal) therapy approaches.
- Focuses on developing treatments for Limb-Girdle Muscular Dystrophy Type 2A (LGMD2A) and Facioscapulohumeral Muscular Dystrophy (FSHD).
- Leverages CRISPR nuclease technology for precise and efficient gene editing.